Editor's note - Express Pharma

Policy shifts test pharma’s resilience

Pharma industry reports 97 deals worth $25.45 billion in October 2026

Does India Pharma Inc need a new blueprint?

The double burden of tighter enforcement, slower implementation

Diversifying beyond the US market

The fine line between reform and risk

India Pharma’s new resilience mantras

Sun Pharma bets on Organon for its next wind

Midst global headwinds, CDSCO cracks down on GLP-1 gold rush

Building India Pharma Inc’s innovation muscle